Antibiotic Therapy for the Irritable Bowel Syndrome
Abstract
The irritable bowel syndrome (IBS) is one of the most common conditions seen in clinical practice. The number of effective pharmacologic agents for IBS is limited, and therapeutic innovation is hampered by a lack of complete understanding of the pathophysiology of the syndrome, which is probably heterogeneous.1 Alterations in the bacterial flora are increasingly considered to be a relevant pathogenetic factor.2 Consequently, probiotics are being studied as treatment for IBS, but the magnitude of improvement in symptoms with probiotics is limited.2 Some studies have suggested that there are beneficial effects with poorly absorbed antibiotics, but the results of the studies . . .
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Interventional studies showing the positive effects of treatments directed at gut microbiota also support the role of microbial alterations in IBD.
“Interventional studies showing the positive effects of treatments directed at gut microbiota also support the role of microbial alterations in IBD [57,58] .”
From Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis (2014) · cites this paper as [57]
The citation lists haven’t been fetched yet
References 12 · Cited by 28
- Authors
- Tack, J.
- Affiliations
- KU Leuven (BE)
- Corresponding author
- Tack, Jan
- ORCID
- Tack, Jan
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 81-82
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2052332740
- Cited by
- 28
- References
- 12
- Citations by year
- 2024: 1 · 2021: 1 · 2020: 1 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 5 · 2013: 4 · 2012: 5
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Health Professions › Pharmacy › Infant Health and Development
- Keywords
- irritable bowel syndrome, antibiotic therapy, probiotics, gut microbiota, bacterial flora, IBS pathophysiology, symptom improvement
- MeSH terms
- Rifaximin, Anti-Bacterial Agents, Humans, Intestinal Absorption, Intestine, Small, Rifamycins, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
